Recent Updates on Nanocarriers for Drug Delivery in Posterior Segment
Diseases with Emphasis on Diabetic Retinopathy

Ravi      Parashar; Amber      Vyas; Abhishek   K.   Sah; Narayan      Hemnani; Pugazhenthan      Thangaraju; Preeti   K.   Suresh
doi:10.2174/0115733998240053231009060654
Abstract

In recent years, various conventional formulations have been used for the treatment and/or management of ocular medical conditions. Diabetic retinopathy, a microvascular disease of the retina, remains the leading cause of visual disability in patients with diabetes. Currently, for treating diabetic retinopathy, only intraocular, intravitreal, periocular injections, and laser photocoagulation are widely used. Frequent administration of these drugs by injections may lead to serious complications, including retinal detachment and endophthalmitis. Although conventional ophthalmic formulations like eye drops, ointments, and suspensions are available globally, these formulations fail to achieve optimum drug therapeutic profile due to immediate nasolacrimal drainage, rapid tearing, and systemic tearing toxicity of the drugs. To achieve better therapeutic outcomes with prolonged release of the therapeutic agents, nano-drug delivery materials have been investigated. These nanocarriers include nanoparticles, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), dendrimers, nanofibers, in-situ gel, vesicular carriers, niosomes, and mucoadhesive systems, among others. The nanocarriers carry the potential benefits of site-specific delivery and controlled and sustained drug release profile. In the present article, various nanomaterials explored for treating diabetic retinopathy are reviewed.
[1]
Delamo E, Urtti A. Current and future ophthalmic drug delivery systemsA shift to the posterior segment. Drug Discov Today  2008; 13(3-4): 135-43.
 [http://dx.doi.org/10.1016/j.drudis.2007.11.002] [PMID: 18275911]

[2]
Janoria KG, Gunda S, Boddu SHS, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv  2007; 4(4): 371-88.
 [http://dx.doi.org/10.1517/17425247.4.4.371] [PMID: 17683251]

[3]
Sah AK, Suresh PK. Recent advances in ocular drug delivery, with special emphasis on lipid based nanocarriers. Recent Pat Nanotechnol  2015; 9(2): 94-105.
 [http://dx.doi.org/10.2174/187221050902150819151841] [PMID: 27009124]

[4]
Suresh PK, Sah AK. Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: Focus on current paradigms and future directions. Expert Opin Drug Deliv  2014; 11(11): 1747-68.
 [http://dx.doi.org/10.1517/17425247.2014.938045] [PMID: 25007007]

[5]
Liu Y, Wu N. Progress of nanotechnology in diabetic retinopathy treatment. Int J Nanomedicine  2021; 16: 1391-403.
 [http://dx.doi.org/10.2147/IJN.S294807]

[6]
Semeraro F, Cancarini A, dell’Omo R, et al. Diabetic retinopathy: Vascular and inflammatory disease. J Diabetes Res  2015; 2015: 582060.
 [http://dx.doi.org/10.1155/2015/582060]

[7]
Amato R, Rossino MG, Cammalleri M, et al. Lisosan G protects the retina from neurovascular damage in experimental diabetic retinopathy. Nutrients  2018; 10(12): 1932.
 [http://dx.doi.org/10.3390/nu10121932]

[8]
Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol  2004; 15(6): 508-18.
 [http://dx.doi.org/10.1097/01.icu.0000143685.60479.3b] [PMID: 15523197]

[9]
Koh BMQR, Banu R, Nusinovici S, Sabanayagam C. 100 most-cited articles on diabetic retinopathy. Br J Ophthalmol  2021; 105(10): 1329-36.
 [http://dx.doi.org/10.1136/bjophthalmol-2020-316609] [PMID: 32855165]

[10]
Davis MD. Diabetic Retinopathy: A clinical overview. Diabetes Care  1992; 15(12): 1844-74.
 [http://dx.doi.org/10.2337/diacare.15.12.1844] [PMID: 1464242]

[11]
Scanlon P, Aldington S, Stratton I. Epidemiological issues in diabetic retinopathy. Middle East Afr J Ophthalmol  2013; 20(4): 293-300.
 [http://dx.doi.org/10.4103/0974-9233.120007] [PMID: 24339678]

[12]
Fung TH, Patel B, Wilmot EG, et al. Diabetic retinopathy for the non-ophthalmologist. Clin Med  2022; 22(2): 112-6.
 [http://dx.doi.org/10.7861/clinmed.2021-0792]

[13]
Ajlan RS, Silva PS, Sun JK. Vascular endothelial growth factor and diabetic retinal disease. Semin Ophthalmol  2016; 31(1-2): 40-8.
 [http://dx.doi.org/10.3109/08820538.2015.1114833]

[14]
Catalani E, Silvestri F, Bongiorni S, et al. Retinal damage in a new model of hyperglycemia induced by high-sucrose diets. Pharmacol Res  2021; 166: 105488.
 [http://dx.doi.org/10.1016/j.phrs.2021.105488] [PMID: 33582248]

[15]
Zhou HR, Ma XF, Lin WJ, et al. Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1/Parkin-mediated mitophagy in diabetic retinopathy. Front Pharmacol  2021; 11: 589114.
 [http://dx.doi.org/10.3389/fphar.2020.589114]

[16]
Fahmideh F, Marchesi N, Campagnoli LIM, et al. Effect of troxerutin in counteracting hyperglycemia-induced VEGF upregulation in endothelial cells: A new option to target early stages of diabetic retinopathy? Front Pharmacol  2022; 13: 951833.
 [http://dx.doi.org/10.3389/fphar.2022.951833]

[17]
Wang H, Sun Y, Ma G, et al. The Relationship between Expression of Nuclear Factor I and the Progressive Occurrence of Diabetic Retinopathy. Comput Math Methods Med  2022; 2022: 1-6.
 [http://dx.doi.org/10.1155/2022/1272729] [PMID: 35669369]

[18]
Liu F, Saul AB, Pichavaram P, et al. Pharmacological inhibition of spermine oxidase reduces neurodegeneration and improves retinal function in diabetic mice. J Clin Med  2020; 9(2): 340.
 [http://dx.doi.org/10.3390/jcm9020340]

[19]
Ivanova E, Bianchimano P, Corona C, et al. Optogenetic stimulation of cholinergic amacrine cells improves capillary blood flow in diabetic retinopathy. Invest Ophthalmol Vis Sci  2020; 61(10): 44.
 [http://dx.doi.org/10.1167/iovs.61.10.44]

[20]
Hernández C, Dal Monte M, Simó R, Casini G. Neuroprotection as a therapeutic target for diabetic retinopathy. J Diabetes Res  2016; 2016: 1-18.
 [http://dx.doi.org/10.1155/2016/9508541] [PMID: 27123463]

[21]
Pusparajah P, Lee LH, Abdul Kadir K. Molecular markers of diabetic retinopathy: Potential screening tool of the future? Front Physiol  2016; 7: 200.
 [http://dx.doi.org/10.3389/fphys.2016.00200]

[22]
Kim HM, Woo SJ. Ocular drug delivery to the retina: Current innovations and future perspective. Pharmaceutics  2021; 13(1): 108.
 [http://dx.doi.org/10.3390/pharmaceutics13010108]

[23]
Djebli N, Khier S, Griguer F, et al. Ocular drug distribution after topical administration: Population pharmacokinetic model in rabbits. Eur J Drug Metab Pharmacokinet  2017; 42(1): 59-68.
 [http://dx.doi.org/10.1007/s13318-016-0319-4]

[24]
Badhani A, Dabral P, Rana V, et al. Evaluation of cyclodextrins for enhancing corneal penetration of natamycin eye drops. J Pharm Bioallied Sci  2012; 4 (Suppl. 1): S29-30.
 [http://dx.doi.org/10.4103/0975-7406.94128]

[25]
Sabermoghadam Ranjbar A, Rajabi O, Salari R, Ashraf H. Lidocaine cyclodextrin complex ophthalmic drop, a new topical anesthetic choice. Iran Red Crescent Med J  2012; 14(9): 569-73.
 [PMID: 23115719]

[26]
Bhowmik M, Kumari P, Sarkar G, et al. Effect of xanthan gum and guar gum on in situ gelling ophthalmic drug delivery system based on poloxamer-407. Int J Biol Macromol  2013; 62: 117-23.
 [http://dx.doi.org/10.1016/j.ijbiomac.2013.08.024] [PMID: 23988556]

[27]
Gevariya H, Patel J. Long acting betaxolol ocular inserts based on polymer composite. Curr Drug Deliv  2013; 10(4): 384-93.
 [http://dx.doi.org/10.2174/1567201811310040003] [PMID: 23909665]

[28]
Li J, Wu L, Wu W, et al. A potential carrier based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine nitrate. Int J Pharm  2013; 455(1-2): 75-84.
 [http://dx.doi.org/10.1016/j.ijpharm.2013.07.057] [PMID: 23916822]

[29]
Zhao X, Seah I, Xue K, et al. Antiangiogenic nanomicelles for the topical delivery of aflibercept to treat retinal neovascular disease. Adv Mater  2022; 34(25): 2108360.
 [http://dx.doi.org/10.1002/adma.202108360] [PMID: 34726299]

[30]
Sadasivam R, Packirisamy G, Goswami M. Biocompatible soft hydrogel lens as topical implants for diabetic retinopathy. Mater Lett  2022; 318: 132174.
 [http://dx.doi.org/10.1016/j.matlet.2022.132174]

[31]
Lorenzo-Soler L, Praphanwittaya P, Olafsdottir OB, et al. Topical noninvasive retinal drug delivery of a tyrosine kinase inhibitor: 3% cediranib maleate cyclodextrin nanoparticle eye drops in the rabbit eye. Acta Ophthalmol  2022; 100(7): 788-96.
 [http://dx.doi.org/10.1111/aos.15101] [PMID: 35080812]

[32]
Varela-Fernández R, Díaz-Tomé V, Luaces-Rodríguez A, et al. Drug delivery to the posterior segment of the eye: Biopharmaceutic and pharmacokinetic considerations. Pharmaceutics  2020; 12(3): 269.
 [http://dx.doi.org/10.3390/pharmaceutics12030269] [PMID: 32188045]

[33]
Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: Prospects of pharmacokinetic modeling. Adv Drug Deliv Rev  2006; 58(11): 1164-81.
 [http://dx.doi.org/10.1016/j.addr.2006.07.025] [PMID: 17069929]

[34]
Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother  2018; 107: 1564-82.
 [http://dx.doi.org/10.1016/j.biopha.2018.08.138] [PMID: 30257375]

[35]
Wang J, Tan J, Luo J, et al. Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy. J Nanobiotechnology  2017; 15(1): 18.
 [http://dx.doi.org/10.1186/s12951-017-0251-z]

[36]
Zhang E, Osipova N, Sokolov M, et al. Exploring the systemic delivery of a poorly water-soluble model drug to the retina using PLGA nanoparticles. Eur J Pharm Sci  2021; 164: 105905.
 [http://dx.doi.org/10.1016/j.ejps.2021.105905] [PMID: 34116175]

[37]
Zhu Y, Li J, Yu S, et al. Clinical comparative study of intravitreal injection of triamcinolone acetonide and aflibercept in the treatment of diabetic retinopathy cystoid macular edema. Emerg Med Int  2022; 2022: 1348855.
 [http://dx.doi.org/10.1155/2022/1348855]

[38]
Li S, Yang Y, Zou J, Zeng J, Ding C. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage. BMC Ophthalmol  2022; 22(1): 63.
 [http://dx.doi.org/10.1186/s12886-022-02303-3] [PMID: 35139812]

[39]
Wang Q, Cai H, Xu D, et al. Pars plana vitrectomy assisted by intravitreal injection of conbercept enhances the therapeutic effect and quality of life in patients with severe proliferative diabetic retinopathy. Am J Transl Res  2022; 14(2): 1324-31.

[40]
Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature  2001; 414(6865): 782-7.
 [http://dx.doi.org/10.1038/414782a] [PMID: 11742409]

[41]
Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology  1991; 98(10): 1594-602.
 [http://dx.doi.org/10.1016/S0161-6420(91)32082-7] [PMID: 1961650]

[42]
Julius A, Hopper W. A non-invasive, multi-target approach to treat diabetic retinopathy. Biomed Pharmacother  2019; 109: 708-15.
 [http://dx.doi.org/10.1016/j.biopha.2018.10.185] [PMID: 30551523]

[43]
Wang R, Gao Y, Liu A, Zhai G. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances. J Drug Target  2021; 29(7): 687-702.
 [http://dx.doi.org/10.1080/1061186X.2021.1878366] [PMID: 33474998]

[44]
Rafiei F, Tabesh H, Farzad F. Sustained subconjunctival drug delivery systems: Current trends and future perspectives. Int Ophthalmol  2020; 40(9): 2385-401.
 [http://dx.doi.org/10.1007/s10792-020-01391-8] [PMID: 32383131]

[45]
Tsai CH, Hoang LN, Lin CC, et al. Evaluation of topical and subconjunctival injection of hyaluronic acid-coated nanoparticles for drug delivery to posterior eye. Pharmaceutics  2022; 14(6): 1253.
 [http://dx.doi.org/10.3390/pharmaceutics14061253] [PMID: 35745825]

[46]
Pandit J, Sultana Y, Aqil M. Chitosan coated nanoparticles for efficient delivery of bevacizumab in the posterior ocular tissues via subconjunctival administration. Carbohydr Polym  2021; 267: 118217.
 [http://dx.doi.org/10.1016/j.carbpol.2021.118217] [PMID: 34119171]

[47]
Johnson CJ, Berglin L, Chrenek MA, Redmond TM, Boatright JH, Nickerson JM. Technical brief: Subretinal injection and electroporation into adult mouse eyes. Mol Vis  2008; 14: 2211-26.
 [PMID: 19057658]

[48]
Peng Y, Tang L, Zhou Y. Subretinal injection: A review on the novel route of therapeutic delivery for vitreoretinal diseases. Ophthalmic Res  2017; 58(4): 217-26.
 [http://dx.doi.org/10.1159/000479157] [PMID: 28858866]

[49]
Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: Therapeutic applications. Adv Drug Deliv Rev  2006; 58(11): 1182-202.
 [http://dx.doi.org/10.1016/j.addr.2006.07.026] [PMID: 17107737]

[50]
Xu H, Zhang L, Gu L, et al. Subretinal delivery of AAV2-mediated human erythropoietin gene is protective and safe in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci  2014; 55(3): 1519-30.
 [http://dx.doi.org/10.1167/iovs.13-13155] [PMID: 24508793]

[51]
Metlapally R, Wildsoet CF. Scleral mechanisms underlying ocular growth and myopia. Prog Mol Biol Transl Sci  2015; 134: 241-8.
 [http://dx.doi.org/10.1016/bs.pmbts.2015.05.005]

[52]
Fangueiro JF, Silva AM, Garcia ML, et al. Current nanotechnology approaches for the treatment and management of diabetic retinopathy. Eur J Pharm Biopharm  2015; 95(Pt B): 307-22.
 [http://dx.doi.org/10.1016/j.ejpb.2014.12.023]

[53]
Ding S. Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today  1998; 1(8): 328-35.
 [http://dx.doi.org/10.1016/S1461-5347(98)00087-X]

[54]
Bochot A, Fattal E, Grossiord JL, Puisieux F, Couvreur P. Characterization of a new ocular delivery system based on a dispersion of liposomes in a thermosensitive gel. Int J Pharm  1998; 162(1-2): 119-27.
 [http://dx.doi.org/10.1016/S0378-5173(97)00419-5]

[55]
Losa C, Calvo P, Castro E, Vila-Jato JL, Alonso MJ. Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles. J Pharm Pharmacol  2011; 43(8): 548-52.
 [http://dx.doi.org/10.1111/j.2042-7158.1991.tb03534.x] [PMID: 1681069]

[56]
Taghe S, Mirzaeei S. Preparation and characterization of novel, mucoadhesive ofloxacin nanoparticles for ocular drug delivery. Braz J Pharm Sci 2019.

[57]
Di Tommaso C, Valamanesh F, Miller F, et al. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. Invest Ophthalmol Vis Sci  2012; 53(4): 2292-9.
 [http://dx.doi.org/10.1167/iovs.11-8829] [PMID: 22427552]

[58]
Kompella UB, Amrite AC, Pacha Ravi R, et al. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res  2013; 36: 172-98.
 [http://dx.doi.org/10.1016/j.preteyeres.2013.04.001]

[59]
Chen H, Li Z, Zhou Z, Zhuang J. Cerium compound-loaded poly(lactic co glycolic acid) nanospheres in improving diabetic retinopathy. Sci Adv Mater  2022; 14(3): 423-9.
 [http://dx.doi.org/10.1166/sam.2022.4181]

[60]
Srinivasarao DA, Sreenivasa Reddy S, Bhanuprakash Reddy G, Katti DS. Simultaneous amelioration of diabetic ocular complications in lens and retinal tissues using a non-invasive drug delivery system. Int J Pharm  2021; 608(608): 121045.
 [http://dx.doi.org/10.1016/j.ijpharm.2021.121045] [PMID: 34481006]

[61]
Mahlumba P, Kumar P, du Toit LC, et al. Fabrication and characterisation of a photo-responsive, injectable nanosystem for sustained delivery of macromolecules. Int J Mol Sci  2021; 22(7): 3359.
 [http://dx.doi.org/10.3390/ijms22073359]

[62]
Radwan SE, El-Kamel A, Zaki EI, et al. Hyaluronic-coated albumin nanoparticles for the non-invasive delivery of apatinib in diabetic retinopathy. Int J Nanomedicine  2021; 16: 4481-94.
 [http://dx.doi.org/10.2147/IJN.S316564]

[63]
Laddha UD, Kshirsagar SJ. Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences. Heliyon  2020; 6(8): e04589.
 [http://dx.doi.org/10.1016/j.heliyon.2020.e04589] [PMID: 32832706]

[64]
Qiu F, Meng T, Chen Q, et al. Fenofibrate-Loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration. Mol Pharm  2019; 16(5): 1958-70.
 [http://dx.doi.org/10.1021/acs.molpharmaceut.8b01319]

[65]
Zeng L, Ma W, Shi L, et al. Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy. Int J Nanomedicine  2019; 14: 6357-69.
 [http://dx.doi.org/10.2147/IJN.S214727]

[66]
Pandit J, Sultana Y, Aqil M. Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. Artif Cells Nanomed Biotechnol  2017; 45(7): 1397-407.
 [http://dx.doi.org/10.1080/21691401.2016.1243545] [PMID: 27855494]

[67]
Schneider-Futschik EK, Reyes-Ortega F. Advantages and disadvantages of using magnetic nanoparticles for the treatment of complicated ocular disorders. Pharmaceutics  2021; 13(8): 1157.
 [http://dx.doi.org/10.3390/pharmaceutics13081157] [PMID: 34452117]

[68]
Bassetto M, Sen M, Poulhes F, et al. New method for efficient sirna delivery in retina explants: Reverse magnetofection. Bioconjug Chem  2021; 32(6): 1078-93.
 [http://dx.doi.org/10.1021/acs.bioconjchem.1c00132] [PMID: 34081855]

[69]
Amato R, Giannaccini M, Dal Monte M, et al. Association of the somatostatin analog octreotide with magnetic nanoparticles for intraocular delivery: A possible approach for the treatment of diabetic retinopathy. Front Bioeng Biotechnol  2020; 8: 144.
 [http://dx.doi.org/10.3389/fbioe.2020.00144]

[70]
Tzameret A, Ketter-Katz H, Edelshtain V, et al. In vivo MRI assessment of bioactive magnetic iron oxide/human serum albumin nanoparticle delivery into the posterior segment of the eye in a rat model of retinal degeneration. J Nanobiotechnology  2019; 17(1): 3.
 [http://dx.doi.org/10.1186/s12951-018-0438-y] [PMID: 30630490]

[71]
Giannaccini M, Pedicini L, De Matienzo G, et al. Magnetic nanoparticles: A strategy to target the choroidal layer in the posterior segment of the eye. Sci Rep  2017; 7: 43092.
 [http://dx.doi.org/10.1038/srep43092]

[72]
SALIMI A. Evaluation of the Effect of Naringenin Liposomal Formulation on Retinopathy in an Experimental Rabbit Model. Kafkas Univ Vet Fak Derg  2022; 28(4)
 [http://dx.doi.org/10.9775/kvfd.2022.27538]

[73]
Navarro-Partida J, Altamirano-Vallejo JC, Aceves Franco LA, et al. Topical triamcinolone acetonide-loaded liposome formulation used as an adjuvant to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Pharmaceutics  2021; 13(9): 1491.
 [http://dx.doi.org/10.3390/pharmaceutics13091491] [PMID: 34575567]

[74]
Anishiya chella daisy ER, Rajendran NK, Jeyaraj M, Ramu A, Rajan M. Retracted article: Retinal photoreceptors targeting SA- g -AA coated multilamellar liposomes carrier system for cytotoxicity and cellular uptake evaluation. J Liposome Res  2021; 31(2): 203-16.
 [http://dx.doi.org/10.1080/08982104.2020.1768111] [PMID: 32396763]

[75]
Riemann S, Kolibabka M, Busch S, et al. Microglial activation is associated with vasoprotection in a rat model of inflammatory retinal vasoregression. Front Physiol  2021; 12: 660164.
 [http://dx.doi.org/10.3389/fphys.2021.660164] [PMID: 33981252]

[76]
Li L, Lai K, Li C, et al. APRPG-modified nanoliposome loaded with miR-146a-5p inhibitor suppressed choroidal neovascularization by targeting endothelial cells. Cutan Ocul Toxicol  2020; 39(4): 354-62.
 [http://dx.doi.org/10.1080/15569527.2020.1823406] [PMID: 32928013]

[77]
Asasutjarit R, Managit C, Phanaksri T, Treesuppharat W, Fuongfuchat A. Formulation development and in vitro evaluation of transferrin-conjugated liposomes as a carrier of ganciclovir targeting the retina. Int J Pharm  2020; 577: 119084.
 [http://dx.doi.org/10.1016/j.ijpharm.2020.119084] [PMID: 31988033]

[78]
Khalil M, Hashmi U, Riaz R, Rukh Abbas S. Chitosan coated liposomes (CCL) containing triamcinolone acetonide for sustained delivery: A potential topical treatment for posterior segment diseases. Int J Biol Macromol  2020; 143: 483-91.
 [http://dx.doi.org/10.1016/j.ijbiomac.2019.10.256] [PMID: 31759018]

[79]
Bogdanov P, Sampedro J, Sola-Adell C, et al. Effects of liposomal formulation of citicoline in experimental diabetes-induced retinal neurodegeneration. Int J Mol Sci  2018; 19(8): 2458.
 [http://dx.doi.org/10.3390/ijms19082458]

[80]
Karumanchi DK, Skrypai Y, Thomas A, Gaillard ER. Rational design of liposomes for sustained release drug delivery of bevacizumab to treat ocular angiogenesis. J Drug Deliv Sci Technol  2018; 47: 275-82.
 [http://dx.doi.org/10.1016/j.jddst.2018.07.003]

[81]
Arta A, Eriksen AZ, Melander F, et al. Endothelial protein C–targeting liposomes show enhanced uptake and improved therapeutic efficacy in human retinal endothelial cells. Invest Ophthalmol Vis Sci  2018; 59(5): 2119-32.
 [http://dx.doi.org/10.1167/iovs.18-23800] [PMID: 29677376]

[82]
Bochot A, Couvreur P, Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res  2000; 19(2): 131-47.
 [http://dx.doi.org/10.1016/S1350-9462(99)00014-2] [PMID: 10674705]

[83]
Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: Basic research to clinical applications. Invest Ophthalmol Vis Sci  2010; 51(11): 5403-20.
 [http://dx.doi.org/10.1167/iovs.10-5392]

[84]
Nirmal J, Radhakrishnan K, Moreno M, et al. Drug, delivery and devices for diabetic retinopathy (3Ds in DR). Expert Opin Drug Deliv  2016; 13(11): 1625-37.
 [http://dx.doi.org/10.1080/17425247.2016.1188800] [PMID: 27169870]

[85]
Gupta SK, Velpandian T, Dhingra N, Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J Ocul Pharmacol Ther  2000; 16(6): 511-8.
 [http://dx.doi.org/10.1089/jop.2000.16.511] [PMID: 11132898]

[86]
Abrishami M, Ganavati SZ, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina  2009; 29(5): 699-703.
 [http://dx.doi.org/10.1097/IAE.0b013e3181a2f42a] [PMID: 19430280]

[87]
Hironaka K, Inokuchi Y, Tozuka Y, Shimazawa M, Hara H, Takeuchi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release  2009; 136(3): 247-53.
 [http://dx.doi.org/10.1016/j.jconrel.2009.02.020] [PMID: 19272407]

[88]
Diebold Y, Jarrín M, Sáez V, et al. Ocular drug delivery by liposome–chitosan nanoparticle complexes (LCS-NP). Biomaterials  2007; 28(8): 1553-64.
 [http://dx.doi.org/10.1016/j.biomaterials.2006.11.028] [PMID: 17169422]

[89]
Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: Novel sustained release nonionic stable vesicular systems-an overview. Adv Colloid Interface Sci  2012; 183-184: 46-54.
 [http://dx.doi.org/10.1016/j.cis.2012.08.002] [PMID: 22947187]

[90]
Gala U, Chauhan H. Taste masking techniques in the pharmaceutical industry. Am Pharm Rev  2014; 17(4)
 [http://dx.doi.org/10.1155/2018/6847971]

[91]
Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. Adv Colloid Interface Sci  1995; 58(1): 1-55.
 [http://dx.doi.org/10.1016/0001-8686(95)00242-I]

[92]
Amoabediny G, Haghiralsadat F, Naderinezhad S, et al. Overview of preparation methods of polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles: A comprehensive review. Int J Polym Mater  2018; 67(6): 383-400.
 [http://dx.doi.org/10.1080/00914037.2017.1332623]

[93]
Rinaldi F, del Favero E, Moeller J, et al. Hydrophilic silver nanoparticles loaded into niosomes: Physical–chemical characterization in view of biological applications. Nanomaterials  2019; 9(8): 1177.
 [http://dx.doi.org/10.3390/nano9081177] [PMID: 31426465]

[94]
Bidram E, Esmaeili Y, Ranji-Burachaloo H, et al. A concise review on cancer treatment methods and delivery systems. J Drug Deliv Sci Technol  2019; 54: 101350.
 [http://dx.doi.org/10.1016/j.jddst.2019.101350]

[95]
Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm  1998; 172(1-2): 33-70.
 [http://dx.doi.org/10.1016/S0378-5173(98)00169-0]

[96]
 AL Qtaish N, Gallego I, Villate- Beitia I, et al. Sphingolipid extracts enhance gene delivery of cationic lipid vesicles into retina and brain. Eur J Pharm Biopharm  2021; 169: 103-12.
 [http://dx.doi.org/10.1016/j.ejpb.2021.09.011] [PMID: 34606927]

[97]
Mashal M, Attia N, Martínez-Navarrete G, et al. Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes. J Control Release  2019; 304: 181-90.
 [http://dx.doi.org/10.1016/j.jconrel.2019.05.010] [PMID: 31071372]

[98]
Gallego I, Villate-Beitia I, Martínez-Navarrete G, et al. Non-viral vectors based on cationic niosomes and minicircle DNA technology enhance gene delivery efficiency for biomedical applications in retinal disorders. Nanomedicine  2019; 17: 308-18.
 [http://dx.doi.org/10.1016/j.nano.2018.12.018] [PMID: 30790710]

[99]
Villate-Beitia I, Gallego I, Martínez-Navarrete G, et al. Polysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administration. Int J Pharm  2018; 550(1-2): 388-97.
 [http://dx.doi.org/10.1016/j.ijpharm.2018.07.035] [PMID: 30009984]

[100]
Qin Y, Tian Y, Liu Y, et al. Hyaluronic acid-modified cationic niosomes for ocular gene delivery: Improving transfection efficiency in retinal pigment epithelium. J Pharm Pharmacol  2018; 70(9): 1139-51.
 [http://dx.doi.org/10.1111/jphp.12940] [PMID: 29931682]

[101]
Mashal M, Attia N, Puras G, Martínez-Navarrete G, Fernández E, Pedraz JL. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60. J Control Release  2017; 254: 55-64.
 [http://dx.doi.org/10.1016/j.jconrel.2017.03.386] [PMID: 28347807]

[102]
Campos EJ, Campos A, Martins J, Ambrósio AF. Opening eyes to nanomedicine: Where we are, challenges and expectations on nanotherapy for diabetic retinopathy. Nanomedicine  2017; 13(6): 2101-13.
 [http://dx.doi.org/10.1016/j.nano.2017.04.008] [PMID: 28428052]

[103]
Quintana A, Raczka E, Piehler L, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res  2002; 19(9): 1310-6.
 [http://dx.doi.org/10.1023/A:1020398624602] [PMID: 12403067]

[104]
Selvaraj K, Gowthamarajan K, Karri VVSR, Barauah UK, Ravisankar V, Jojo GM. Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy. J Drug Target  2017; 25(5): 386-405.
 [http://dx.doi.org/10.1080/1061186X.2017.1280809] [PMID: 28122462]

[105]
Cheng Y, Xu Z, Ma M, Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci  2008; 97(1): 123-43.
 [http://dx.doi.org/10.1002/jps.21079] [PMID: 17721949]

[106]
Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today  2001; 6(8): 427-36.
 [http://dx.doi.org/10.1016/S1359-6446(01)01757-3] [PMID: 11301287]

[107]
Hecht S, Fréchet JMJ. Dendritic encapsulation of function: Applying nature’s site isolation principle from biomimetics to materials science. Angew Chem Int Ed  2001; 40(1): 74-91.
 [http://dx.doi.org/10.1002/1521-3773(20010105)40:1<74:AID-ANIE74>3.0.CO;2-C] [PMID: 11169692]

[108]
Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev  2012; 64: 102-15.
 [http://dx.doi.org/10.1016/j.addr.2012.09.030] [PMID: 16305813]

[109]
Holden CA, Tyagi P, Thakur A, et al. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine  2012; 8(5): 776-83.
 [http://dx.doi.org/10.1016/j.nano.2011.08.018] [PMID: 21930109]

[110]
Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release  2005; 102(1): 23-38.
 [http://dx.doi.org/10.1016/j.jconrel.2004.09.015] [PMID: 15653131]

[111]
Garden GA, Möller T. Microglia biology in health and disease. J Neuroimmune Pharmacol  2006; 1(2): 127-37.
 [http://dx.doi.org/10.1007/s11481-006-9015-5] [PMID: 18040779]

[112]
Madaan K, Kumar S, Poonia N, et al. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci  2014; 6(3): 139-50.
 [http://dx.doi.org/10.4103/0975-7406.130965]

[113]
Kambhampati SP, Clunies-Ross AJ, Bhutto I, et al. Systemic and intravitreal delivery of dendrimers to activated microglia/macrophage in ischemia/reperfusion mouse retina. Invest Ophthalmol Vis Sci  2015; 56(8): 4413-24.
 [http://dx.doi.org/10.1167/iovs.14-16250]

[114]
Seitz R, Ohlmann A, Tamm ER. The role of Müller glia and microglia in glaucoma. Cell Tissue Res  2013; 353(2): 339-45.
 [http://dx.doi.org/10.1007/s00441-013-1666-y] [PMID: 23779255]

[115]
Grigsby JG, Cardona SM, Pouw CE, et al. The role of microglia in diabetic retinopathy. J Ophthalmol  2014; 2014: 705783.
 [http://dx.doi.org/10.1155/2014/705783]

[116]
Sun C, Li X, He X, Zhang Q, Tao Y. Neuroprotective effect of minocycline in a rat model of branch retinal vein occlusion. Exp Eye Res  2013; 113: 105-16.
 [http://dx.doi.org/10.1016/j.exer.2013.05.018] [PMID: 23748101]

[117]
Alshammari RA, Aleanizy FS, Aldarwesh A, et al. Retinal delivery of the protein kinase C-β inhibitor ruboxistaurin using non-invasive nanoparticles of polyamidoamine dendrimers. Pharmaceutics  2022; 14(7): 1444.
 [http://dx.doi.org/10.3390/pharmaceutics14071444] [PMID: 35890338]

[118]
Cho H, Kambhampati SP, Lai MJ, et al. Dendrimer-triamcinolone acetonide reduces neuroinflammation, pathological angiogenesis, and neuroretinal dysfunction in ischemic retinopathy. Adv Ther  2021; 4(2): 2000181.
 [http://dx.doi.org/10.1002/adtp.202000181]

[119]
Tan G, Liu D, Zhu R, Pan H, Li J, Pan W. A core-shell nanoplatform as a nonviral vector for targeted delivery of genes to the retina. Acta Biomater  2021; 134: 605-20.
 [http://dx.doi.org/10.1016/j.actbio.2021.07.053] [PMID: 34329781]

[120]
You S, Kim H, Jung H, et al. Tuning surface functionalities of sub-10 nm-sized nanocarriers to target outer retina in designing drug delivery agents for intravitreal administration. Biomaterials  2020; 255: 120188.
 [http://dx.doi.org/10.1016/j.biomaterials.2020.120188] [PMID: 32652402]

[121]
Yang X, Wang L, Li L, et al. A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment. Drug Deliv  2019; 26(1): 989-1001.
 [http://dx.doi.org/10.1080/10717544.2019.1667455]

[122]
Dąbkowska M, Rogińska D, Kłos P, et al. Electrostatic complex of neurotrophin 4 with dendrimer nanoparticles: controlled release of protein in vitro and in vivo. Int J Nanomedicine  2019; 14: 6117-31.
 [http://dx.doi.org/10.2147/IJN.S210140] [PMID: 31534337]

[123]
Ghosh S, Shang P, Terasaki H, et al. A role for βA3/A1-crystallin in type 2 EMT of RPE cells occurring in dry age-related macular degeneration. Invest Ophthalmol Vis Sci  2018; 59(4): AMD104-13.
 [http://dx.doi.org/10.1167/iovs.18-24132] [PMID: 30098172]

[124]
Lancina MG III, Wang J, Williamson GS, Yang H. DenTimol as a dendrimeric timolol analogue for glaucoma therapy: Synthesis and preliminary efficacy and safety assessment. Mol Pharm  2018; 15(7): 2883-9.
 [http://dx.doi.org/10.1021/acs.molpharmaceut.8b00401] [PMID: 29767982]

[125]
Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv  2010; 17(7): 467-89.
 [http://dx.doi.org/10.3109/10717544.2010.483257] [PMID: 20491540]

[126]
de Oliveira IF, Barbosa EJ, Peters MCC, et al. Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers. Int J Pharm  2020; 589: 119831.
 [http://dx.doi.org/10.1016/j.ijpharm.2020.119831] [PMID: 32877729]

[127]
Puglia C, Santonocito D, Romeo G, et al. Lipid nanoparticles traverse non-corneal path to reach the posterior eye segment: in vivo evidence. Molecules  2021; 26(15): 4673.
 [http://dx.doi.org/10.3390/molecules26154673]

[128]
Zhu Y, Sheng Y. RETRACTED: Sustained delivery of epalrestat to the retina using PEGylated solid lipid nanoparticles laden contact lens. Int J Pharm  2020; 587: 119688.
 [http://dx.doi.org/10.1016/j.ijpharm.2020.119688] [PMID: 32717281]

[129]
Tatke A, Dudhipala N, Janga KY, et al. In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: Tear kinetics and ocular disposition studies. Nanomaterials  2018; 9(1): 33.
 [http://dx.doi.org/10.3390/nano9010033]

[130]
Azevedo de Freitas LG, Cruvinel Isaac DL. Lima Em. Retinal changes in rabbit after intravitreal injection of sunitinib encapsulated into solid lipid nanoparticles and polymeric nanocapsules. Arq Bras Oftalmol  2018; 81(5): 408-13.
 [http://dx.doi.org/10.5935/0004-2749.20180079] [PMID: 30208143]

[131]
Du S, Wang H, Jiang F, Wang Y. Diabetic retinopathy analysis—effects of nanoparticle-based triamcinolone. J Nanosci Nanotechnol  2020; 20(10): 6111-5.
 [http://dx.doi.org/10.1166/jnn.2020.18569] [PMID: 32384959]

[132]
Li C, Zhao G, Lu L, Du X. Effect of triamcinolone acetonide-loaded nanoparticles on diabetic retinopathy in rats. Mater Express  2020; 10(9): 1511-7.
 [http://dx.doi.org/10.1166/mex.2020.1784]

[133]
Selvaraj K, Kuppusamy G, Krishnamurthy J, Mahalingam R, Singh SK, Gulati M. Repositioning of itraconazole for the management of ocular neovascularization through surface-modified nanostructured lipid carriers. Assay Drug Dev Technol  2019; 17(4): 178-90.
 [http://dx.doi.org/10.1089/adt.2018.898] [PMID: 30835139]

[134]
Puglia C, Blasi P, Ostacolo C, et al. Innovative nanoparticles enhance N-palmitoylethanolamide intraocular delivery. Front Pharmacol  2018; 9: 285.
 [http://dx.doi.org/10.3389/fphar.2018.00285]

[135]
Lou J, Hu W, Tian R, et al. Optimization and evaluation of a thermoresponsive ophthalmic in situ gel containing curcumin-loaded albumin nanoparticles. Int J Nanomedicine  2014; 9: 2517.
 [http://dx.doi.org/10.2147/IJN.S60270]

[136]
Hsiue GH, Chang RW, Wang CH, Lee SH. Development of in situ thermosensitive drug vehicles for glaucoma therapy. Biomaterials  2003; 24(13): 2423-30.
 [http://dx.doi.org/10.1016/S0142-9612(03)00035-8] [PMID: 12699680]

[137]
Jeong B, Gutowska A. Lessons from nature: Stimuli-responsive polymers and their biomedical applications. Trends Biotechnol  2002; 20(7): 305-11.
 [http://dx.doi.org/10.1016/S0167-7799(02)01962-5] [PMID: 12062976]

[138]
Song L, Lin C, Wang L, Sheng HL, Zhou YF, Nie WY. Fabrication of teardrop-shaped silica particles in polyelectrolyte diluted solution through in situ sol–gel process. J Sol-Gel Sci Technol  2011; 58(3): 651-5.
 [http://dx.doi.org/10.1007/s10971-011-2440-9]

[139]
Cho K, Chung TW, Kim BC, et al. Release of ciprofloxacin from poloxamer-graft-hyaluronic acid hydrogels in vitro. Int J Pharm  2003; 260(1): 83-91.
 [http://dx.doi.org/10.1016/S0378-5173(03)00259-X] [PMID: 12818813]

[140]
Esteruelas G, Halbaut L, García-Torra V, et al. Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment. Int J Pharm  2022; 612: 121379.
 [http://dx.doi.org/10.1016/j.ijpharm.2021.121379] [PMID: 34915146]

[141]
Wu W, Cao W, Chen J, Cai Y, Dong B, Chu X. In situ liquid crystal gel as a promising strategy for improving ocular administration of Dexamethasone: Preparation, characterization, and evaluation. AAPS PharmSciTech  2021; 23(1): 36.
 [http://dx.doi.org/10.1208/s12249-021-02193-6] [PMID: 34951001]

[142]
Deguchi S, Ogata F, Yamaguchi M, et al. In situ gel incorporating disulfiram nanoparticles rescues the retinal dysfunction via ATP collapse in otsuka long–evans tokushima fatty rats. Cells  2020; 9(10): 2171.
 [http://dx.doi.org/10.3390/cells9102171] [PMID: 32993012]

[143]
Du M, Shen S, Liang L, et al. Evaluations of the chuanqi ophthalmic microemulsion in situ gel on dry age-related macular degeneration treatment. Evid Based Complement Alternat Med  2020; 2020: 1-14.
 [http://dx.doi.org/10.1155/2020/3805967]

[144]
Sapino S, Peira E, Chirio D, et al. Thermosensitive nanocomposite hydrogels for intravitreal delivery of Cefuroxime. Nanomaterials  2019; 9(10): 1461.
 [http://dx.doi.org/10.3390/nano9101461]

[145]
Chen CW, Lu DW, Yeh MK, et al. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells. Int J Nanomedicine  2011; 6: 2567-80.
 [http://dx.doi.org/10.2147/IJN.S24447]

[146]
Lee J, Goh U, Lee HJ, Kim J, Jeong M, Park JH. Effective retinal penetration of lipophilic and lipid-conjugated hydrophilic agents delivered by engineered liposomes. Mol Pharm  2017; 14(2): 423-30.
 [http://dx.doi.org/10.1021/acs.molpharmaceut.6b00864] [PMID: 27936751]

[147]
Ceulemans J, Ludwig A. Recent advances on bioadhesive ocular dosage forms. Scientific reviews 2002.

[148]
Durrani AM, Farr SJ, Kellaway IW. Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in the rabbit eye. Int J Pharm  1995; 118(2): 243-50.
 [http://dx.doi.org/10.1016/0378-5173(94)00389-M]

[149]
Hornof M, Weyemberg W, Ludwig AJJCR. Ocular insert using bioadhesive polymer. J Control Release  2003; 89: 419-28.
 [http://dx.doi.org/10.1016/S0168-3659(03)00135-4] [PMID: 12737844]

[150]
Meng J, Sturgis TF, Youan BB. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci  2011; 44(1-2): 57-67.
 [http://dx.doi.org/10.1016/j.ejps.2011.06.007]

[151]
Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev  2001; 52(2): 117-26.
 [http://dx.doi.org/10.1016/S0169-409X(01)00231-9] [PMID: 11718935]

[152]
Khin SY, Soe HMSH, Chansriniyom C, et al. Development of fenofibrate/randomly methylated β-cyclodextrin-loaded Eudragit® RL 100 nanoparticles for ocular delivery. Molecules  2022; 27(15): 4755.
 [http://dx.doi.org/10.3390/molecules27154755] [PMID: 35897940]

[153]
Ricci F, Racaniello GF, Lopedota A, et al. Chitosan/sulfobutylether-β-cyclodextrin based nanoparticles coated with thiolated hyaluronic acid for indomethacin ophthalmic delivery. Int J Pharm  2022; 622: 121905.
 [http://dx.doi.org/10.1016/j.ijpharm.2022.121905] [PMID: 35697201]

[154]
Zoratto N, Forcina L, Matassa R, et al. Hyaluronan-cholesterol nanogels for the enhancement of the ocular delivery of therapeutics. Pharmaceutics  1781; 13(11): 1781.
 [http://dx.doi.org/10.3390/pharmaceutics13111781]

[155]
Wang Y, Zhou L, Fang L, Cao F. Multifunctional carboxymethyl chitosan derivatives-layered double hydroxide hybrid nanocomposites for efficient drug delivery to the posterior segment of the eye. Acta Biomater  2020; 104: 104-14.
 [http://dx.doi.org/10.1016/j.actbio.2020.01.008] [PMID: 31931169]

[156]
Chen S, Jia H, Cui X, et al. Characterization of stimuli-responsive and cross-linked nanohydrogels for applications in ophthalmiatrics therapy. Appl Nanosci  2020; 10(9): 3465-75.
 [http://dx.doi.org/10.1007/s13204-020-01450-7]

[157]
Di Prima G, Saladino S, Bongiovì F, et al. Novel inulin-based mucoadhesive micelles loaded with corticosteroids as potential transcorneal permeation enhancers. Eur J Pharm Biopharm  2017; 117: 385-99.
 [http://dx.doi.org/10.1016/j.ejpb.2017.05.005] [PMID: 28512019]

[158]
Guo C, Li M, Qi X, et al. Intranasal delivery of nanomicelle curcumin promotes corneal epithelial wound healing in streptozotocin-induced diabetic mice. Sci Rep  2016; 6: 29753.
 [http://dx.doi.org/10.1038/srep29753]

[159]
Singh P, Verma N. A review on impact of nanomicelle for ocular drug delivery system. Int J Pharm Sci Res  2018; 9(4): 1397-404.

[160]
Vaishya RD, Khurana V, Patel S, et al. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2014; 6(5): 422-37.
 [http://dx.doi.org/10.1002/wnan.1272]

[161]
Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: Strategies and underlying principles. Nanomedicine  2010; 5(3): 485-505.
 [http://dx.doi.org/10.2217/nnm.10.10]

[162]
Vadlapudi AD, Mitra AK. Nanomicelles: An emerging platform for drug delivery to the eye. Ther Deliv  2013; 4(1): 1-3.
 [http://dx.doi.org/10.4155/tde.12.122]

[163]
Cholkar K, Patel A, Vadlapudi AD, et al. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat Nanomed  2012; 2(2): 82-95.
 [http://dx.doi.org/10.2174/1877912311202020082]

[164]
Velagaleti P, Anglade E, Khan I, et al. Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior and posterior segments of the eye. Drug Deliv Technol  2010; 10(4): 42-7.

[165]
S L J. Gupta N V. Diabetic retinopathy: An inclusive review on current treatment and management approaches. Asian J Pharm Clin Res  2018; 11(11): 54.
 [http://dx.doi.org/10.22159/ajpcr.2018.v11i11.26949]

[166]
Rangel-Yagui CO, Pessoa A Jr, Tavares LC. Micellar solubilization of drugs. J Pharm Pharm Sci  2005; 8(2): 147-65.
 [PMID: 16124926]

[167]
Gothwal A, Khan I, Gupta U. Polymeric micelles: Recent advancements in the delivery of anticancer drugs. Pharm Res  2016; 33(1): 18-39.
 [http://dx.doi.org/10.1007/s11095-015-1784-1] [PMID: 26381278]

[168]
Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett  1990; 268(1): 235-7.
 [http://dx.doi.org/10.1016/0014-5793(90)81016-H] [PMID: 2384160]

[169]
Mandal A, Bisht R, Rupenthal ID, et al. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Control Release  2017; 248: 96-116.
 [http://dx.doi.org/10.1016/j.jconrel.2017.01.012]

[170]
Li J, Li Z, Zhou T, et al. Positively charged micelles based on a triblock copolymer demonstrate enhanced corneal penetration. Int J Nanomedicine  2015; 10: 6027-37.
 [http://dx.doi.org/10.2147/IJN.S90347]

[171]
Luo L, Tam J, Maysinger D, Eisenberg A. Cellular internalization of Poly(ethylene oxide)- b -poly(ε-caprolactone) Diblock Copolymer Micelles. Bioconjug Chem  2002; 13(6): 1259-65.
 [http://dx.doi.org/10.1021/bc025524y] [PMID: 12440861]

[172]
Allen C, Yu Y, Eisenberg A, Maysinger D. Cellular internalization of PCL20-b-PEO44 block copolymer micelles. Biochim Biophys Acta Biomembr  1999; 1421(1): 32-8.
 [http://dx.doi.org/10.1016/S0005-2736(99)00108-X] [PMID: 10561469]

[173]
Savić R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science  2003; 300(5619): 615-8.
 [http://dx.doi.org/10.1126/science.1078192] [PMID: 12714738]

[174]
Liu S, Jones L, Gu FX. Nanomaterials for ocular drug delivery. Macromol Biosci  2012; 12(5): 608-20.
 [http://dx.doi.org/10.1002/mabi.201100419] [PMID: 22508445]

[175]
Di Tommaso C, Bourges JL, Valamanesh F, et al. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Eur J Pharm Biopharm  2012; 81(2): 257-64.
 [http://dx.doi.org/10.1016/j.ejpb.2012.02.014] [PMID: 22445900]

[176]
Ponnusamy C, Sugumaran A, Krishnaswami V, et al. Development and evaluation of polyvinylpyrrolidone K90 and poloxamer 407 self-assembled nanomicelles: Enhanced topical ocular delivery of artemisinin 2021; 13(18): 3038.
 [http://dx.doi.org/10.3390/polym13183038]

[177]
Rassu G, Pavan B, Mandracchia D, et al. Polymeric nanomicelles based on inulin D α-tocopherol succinate for the treatment of diabetic retinopathy. J Drug Deliv Sci Technol  2021; 61: 102286.
 [http://dx.doi.org/10.1016/j.jddst.2020.102286]

[178]
Gote V, Mandal A, Alshamrani M, et al. Self-assembling tacrolimus nanomicelles for retinal drug delivery. Pharmaceutics  2020; 12(11): 1072.
 [http://dx.doi.org/10.3390/pharmaceutics12111072]

[179]
Nagaraj R, Stack T, Yi S, et al. High density display of an anti-angiogenic peptide on micelle surfaces enhances their inhibition of αvβ3 integrin-mediated neovascularization in vitro. Nanomaterials  2020; 10(3): 581.
 [http://dx.doi.org/10.3390/nano10030581] [PMID: 32235802]

[180]
Bongiovì F, Fiorica C, Palumbo FS, Di Prima G, Giammona G, Pitarresi G. Imatinib-loaded micelles of hyaluronic acid derivatives for potential treatment of neovascular ocular diseases. Mol Pharm  2018; 15(11): 5031-45.
 [http://dx.doi.org/10.1021/acs.molpharmaceut.8b00620] [PMID: 30248267]

[181]
Sadeghi MS, Alavi S, Haeri A, et al. Tacrolimus phospholipid based nanomicelles as a potential local delivery system for corneal neovascularization therapy. International Pharmacy Acta  2018; 1(2): 198-207.
 [http://dx.doi.org/10.22037/ipa.v1i2.21531]

[182]
Mandal A, Cholkar K, Khurana V, et al. Topical formulation of self-assembled antiviral prodrug nanomicelles for targeted retinal delivery. Mol Pharm  2017; 14(6): 2056-69.
 [http://dx.doi.org/10.1021/acs.molpharmaceut.7b00128] [PMID: 28471177]

[183]
Simonazzi A, Cid AG, Villegas M, et al. Nanotechnology applications in drug controlled release Drug targeting and stimuli sensitive drug delivery systems.  Elsevier 2018; pp. 81-116.
 [http://dx.doi.org/10.1016/B978-0-12-813689-8.00003-3]

[184]
Peters MCC, Santos Neto E, Monteiro LM, et al. Advances in ophthalmic preparation: The role of drug nanocrystals and lipid-based nanosystems. J Drug Target  2020; 28(3): 259-70.
 [http://dx.doi.org/10.1080/1061186X.2019.1663858] [PMID: 31491352]

[185]
Ganta S, Talekar M, Singh A, Coleman TP, Amiji MM. Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech  2014; 15(3): 694-708.
 [http://dx.doi.org/10.1208/s12249-014-0088-9] [PMID: 24510526]

[186]
John M, Gacche RN. Nano-formulations for ophthalmic treatments. Archives of Pharmacy and Pharmaceutical Sciences 2017.
 [http://dx.doi.org/10.29328/journal.hps.1001005]

[187]
Qamar Z, Qizilbash FF, Iqubal MK, et al. Nano-based drug delivery system: Recent strategies for the treatment of ocular disease and future perspective. Recent Pat Drug Deliv Formul  2019; 13(4): 246-54.
 [http://dx.doi.org/10.2174/1872211314666191224115211]

[188]
Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM. W/O microemulsions for ocular delivery: Evaluation of ocular irritation and precorneal retention. J Control Release  2006; 111(1-2): 145-52.
 [http://dx.doi.org/10.1016/j.jconrel.2005.11.020] [PMID: 16426694]

[189]
Zhang T, Jiao X, Peng X, et al. Non-invasive drug delivery systems mediated by nanocarriers and molecular dynamics simulation for posterior eye disease therapeutics: Virtual screening, construction and comparison. J Mol Liq  2022; 363: 119805.
 [http://dx.doi.org/10.1016/j.molliq.2022.119805]

[190]
Zhang H, Dong W, Long C, Li Q. Mechanism of propofol-lidocaine hydrochloride nano-emulsion on retinal ganglion cytopathic effect in diabetic rats. J Biomater Tissue Eng  2022; 12(1): 36-44.
 [http://dx.doi.org/10.1166/jbt.2022.2868]

[191]
Huang L, Liang W, Zhou K, et al. Therapeutic effects of fenofibrate nano-emulsion eye drops on retinal vascular leakage and neovascularization. Biology  2021; 10(12): 1328.
 [http://dx.doi.org/10.3390/biology10121328]

[192]
Nayak K, Misra M. Triamcinolone acetonide-loaded PEGylated microemulsion for the posterior segment of eye. ACS Omega  2020; 5(14): 7928-39.
 [http://dx.doi.org/10.1021/acsomega.9b04244]

[193]
Taskar P, Adelli G, Patil A, et al. Analog derivatization of cannabidiol for improved ocular permeation. J Ocul Pharmacol Ther  2019; 35(5): 301-10.
 [http://dx.doi.org/10.1089/jop.2018.0141] [PMID: 30998110]

[194]
Said AM, Zaki RG, Salah Eldin RA, et al. Efficacy of Intravitreal injection of 2-Methoxyestradiol in regression of neovascularization of a retinopathy of prematurity rat model. BMC Ophthalmol  2017; 17(1): 38.
 [http://dx.doi.org/10.1186/s12886-017-0433-3]

[195]
Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release  2014; 193: 100-12.
 [http://dx.doi.org/10.1016/j.jconrel.2014.05.031] [PMID: 24862316]

[196]
Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: An advanced mode of drug delivery system. 3 Biotech  2015; 5(2): 123-7.
 [http://dx.doi.org/10.1007/s13205-014-0214-0]

[197]
Sahoo S, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today  2008; 13(3-4): 144-51.
 [http://dx.doi.org/10.1016/j.drudis.2007.10.021] [PMID: 18275912]

[198]
Patel RB, Patel MR, Thakore SD, et al. Nanoemulsion as a valuable nanostructure platform for pharmaceutical drug delivery Nano-and Microscale Drug Delivery Systems.  Elsevier 2017; pp. 321-41.
 [http://dx.doi.org/10.1016/B978-0-323-52727-9.00017-0]

[199]
Dogra A, Kaur K, Ali J, Baboota S, Narang RS, Narang JK. Nanoformulations for ocular delivery of drugs-a patent perspective. Recent Pat Drug Deliv Formul  2020; 13(4): 255-72.
 [http://dx.doi.org/10.2174/1872211314666200127101149] [PMID: 31985387]

[200]
Ako-Adounvo AM, Nagarwal RC, Oliveira L, et al. Recent patents on ophthalmic nanoformulations and therapeutic implications. Recent Pat Drug Deliv Formul  2014; 8(3): 193-201.
 [http://dx.doi.org/10.2174/1872211308666140926112000]

[201]
Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: in vivo performances. J Control Release  2012; 160(3): 418-30.
 [http://dx.doi.org/10.1016/j.jconrel.2012.03.013] [PMID: 22465393]

[202]
Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol  2010; 56(7): 827-40.
 [http://dx.doi.org/10.1211/0022357023691] [PMID: 15233860]

[203]
Wu Y, Vora LK, Mishra D, et al. Nanosuspension-loaded dissolving bilayer microneedles for hydrophobic drug delivery to the posterior segment of the eye. Biomaterials Advances  2022; 137: 212767.
 [http://dx.doi.org/10.1016/j.bioadv.2022.212767] [PMID: 35929230]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0115733998240053231009060654	Print ISSN 1573-3998
Publisher Name Bentham Science Publisher	Online ISSN 1875-6417
Current Diabetes Reviews

Recent Updates on Nanocarriers for Drug Delivery in Posterior Segment Diseases with Emphasis on Diabetic Retinopathy

Abstract Play Pause

Related Journals

Related Books

Abstract
